I specialize in economics as it applies to life sciences and pharmaceuticals, antitrust and competition disputes, and intellectual property valuation. I have performed quantitative analysis to evaluate economic damages in matters involving clinical trial misconduct, early stage technology valuations, commercial success as a secondary consideration of non-obviousness, lost profits, and reasonable royalty analyses.